Skip to Content

93 B9 (Buprenorphine Hydrochloride and Naloxone Hydrochloride (Sublingual) 2 mg (base) / 0.5 mg (base))

Pill with imprint 93 B9 is White, Capsule-shape and has been identified as Buprenorphine hydrochloride and naloxone hydrochloride (sublingual) 2 mg (base) / 0.5 mg (base). It is supplied by Teva Pharmaceuticals USA Inc..

Buprenorphine/naloxone is used in the treatment of opiate dependence and belongs to the drug class narcotic analgesic combinations. Risk cannot be ruled out during pregnancy. Buprenorphine/naloxone 2 mg (base) / 0.5 mg (base) is classified as a Schedule 3 controlled substance under the Controlled Substance Act (CSA).

Images for 93 B9

Buprenorphine hydrochloride and naloxone hydrochloride (sublingual)

93 B9
2 mg (base) / 0.5 mg (base)
Prescription only
Drug Class:
Narcotic analgesic combinations
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
3 - Moderate abuse potential
Labeler / Supplier:
Teva Pharmaceuticals USA Inc.
National Drug Code (NDC):

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2018, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.